The Living Guidelines: Preventing Thromboembolism Polling Results for CLASS IIb Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIb Guidelines
1. In patients 75 y of age and older at increased risk of bleeding but without frank contraindications to oral anticoagulant therapy, and in other patients with moderate risk factors for thromboembolism who are unable to safely tolerate anticoagulation at the standard intensity of INR 2.0 to 3.0, a lower INR target of 2.0 (range 1.6 to 2.5) may be considered for primary prevention of ischemic stroke and systemic embolism. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 1 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III 2. When surgical procedures require interruption of oral anticoagulant therapy for longer than 1 week in high-risk patients, unfractionated heparin may be administered or low molecular weight heparin given by subcutaneous injection, although the efficacy of these alternatives in this situation is uncertain. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 2 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III 3. Following percutaneous coronary intervention or revascularization surgery in patients with AF, low dose aspirin (less than 100 mg per d) and/or clopidogrel (75 mg per d) may be given concurrently with anticoagulation to prevent myocardial ischemic events, but these strategies have not been thoroughly evaluated and are associated with an increased risk of bleeding. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 3 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III 4. In patients undergoing percutaneous coronary intervention, anticoagulation may be interrupted to prevent bleeding at the site of peripheral arterial puncture, but the vitamin K antagonist should be resumed as soon as possible after the procedure and the dose adjusted to achieve an INR in the therapeutic range. Aspirin may be given temporarily during the hiatus, but the maintenance regimen should then consist of the combination of clopidogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0). Clopidogrel should be given for a minimum of 1 month after implantation of a bare metal stent, at least 3 months for a sirolimus-eluting stent, at least 6 months for a paclitaxel-eluting stent, and 12 months or longer in selected patients, following which warfarin may be continued as monotherapy in the absence of a subsequent coronary event. When warfarin is given in combination with clopidogrel or low-dose aspirin, the dose intensity must be carefully regulated. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 4 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III 5. In patients with AF younger than 60 y without heart disease or risk factors for thromboembolism (lone AF), the risk of thromboembolism is low without treatment and the effectiveness of aspirin for primary prevention of stroke relative to the risk of bleeding has not been established. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 5 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III 6. In patients with AF who sustain ischemic stroke or systemic embolism during treatment with low intensity anticoagulation (INR 2.0 to 3.0), rather than add an antiplatelet agent, it may be reasonable to raise the intensity of anticoagulation to a maximum target INR of 3.0 to 3.5. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 6 for preventing thromboembolism should be: CLASS I CLASS IIa CLASS IIb CLASS III